관련링크
본문
BOSTON--( / ) May 16, 2018 -- Cerveau Technologies Inc. today announced an agreement with the Tokyo Metropolitan Institute of Gerontology in Japan to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
As part of the agreement, Cerveau will contract with Tokyo Metropolitan Institute of Gerontology to manufacture and supply the [18F]MK-6240 needed for initiatives in the Tokyo area.
According to Dr. Kenji Ishii, Head of Neuroimaging Research, at Tokyo Metropolitan Institute of Gerontology, “This new generation of tau PET tracer will help us to understand the neuropathological mechanisms of Alzheimer’s disease and other neurodegenerative disorders in the living human brains. The clinical and clinico-pathological studies incorporating tau PET imaging techniques will strongly facilitate the development of disease modifying drugs for Alzheimer’s disease and taupathies.”
“Cerveau welcomes this opportunity to work with the researchers at the Tokyo Metropolitan Institute of Technology to understand the application of MK-6240 and how it may benefit patients with brain diseases. With Japan’s rapidly aging population, the challenge of Alzheimer’s Disease in this country is daunting. The collaboration with TMIG will provide access to our pharmaceutical partners in support of various therapy trials and support our global production network in Europe, Canada, Japan, China, Singapore, Australia and the United States, as well as facilitate novel research at TMIG in the pursuit of evaluating potential preventive treatment options for Alzheimer’s disease,” said Rick Hiatt, President and CEO of Cerveau Technologies, Inc.
About Tokyo Metropolitan Institute of Gerontology
Tokyo Metropolitan Institute of Gerontology (TMIG) was established in 1972 along with Tokyo Metropolitan Geriatric Hospital (TMGH) as the first integrated center for gerontology and geriatric medicine in Japan. The PET facility (TMIG PET Center) was founded in 1990 as an attachment of TMIG. Since then, TMIG PET Center conducted research mainly focused on aging and age-related disorders of the brain. Forty-eight PET tracers have been made available for the clinical PET studies and, among them, TMIG PET Center carried out nine first-in-human studies for brand new PET tracers. In 2013, TMIG PET Center moved to a new building and became equipped for GMP drug production. Recently, the main focus of TMIG PET Center has been on dementia research, collaborating with clinical neurology, psychiatry, neuroradiology, and neuropathology (brain bank) groups of TMGH and other hospitals, and participating in multi-center clinical research projects such as Japanese ADNI and DIAN-Japan, and many clinical trials for Alzheimer’s disease.
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau‘s vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
SAN 공덕동풀팟홀덤 SAN& PENNINGTON, N.J.--( / ) January 17, 아현동풀팟홀덤 2020 -- OncoSec Medical Incorporated (NASDAQ: 경포동홀덤대회 SAN(the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today 성인플래시 announced that its Board of Directors (the “Board”) has 아현동풀팟홀덤 떡마차 determined 성인플래시 물사냥 the Alpha Holdings, Inc. (“Alpha”) 성인플래시 proposal conveying a 아현동풀팟홀덤 여친만드는법 preliminary financing offer is not in the best interests of all shareholders.
After receiving Alpha’s offer, the Board appointed a Special Committee composed 아현동풀팟홀덤 밤에만넷 of independent directors 성인플래시 위야넷 to carefully evaluate Alpha’s proposal. Following its evaluation, the Special Committee unanimously recommended that the Company not pursue Alpha’s proposal due to numerous javfor Afterand potentially 아현동풀팟홀덤 value-destructive elements, and 아현동풀팟홀덤 the Board agreed with this recommendation.
OncoSec continues to urge shareholders to 아현동풀팟홀덤 일본성인영화 OncoSecon the WHITE proxy card FOR the proposed strategic investment by 아현동풀팟홀덤 붕가붕가 and partnership (the “CGP/Sirtex Transaction”) 성인플래시 걸천사 with Grand Decade Developments Limited, a wholly owned subsidiary of China 성인플래시 여자친구감동시키기 Grand Pharmaceutical and Healthcare Holdings Limited 바나나몰 OncoSecand its U.S. affiliate, Sirtex Medical US Holdings, Inc. (“Sirtex”).
OncoSec President and Chief Executive Officer, 성인플래시 레드존 Daniel J. O’Connor, said, “Far from being an actual offer, Alpha’s ‘proposal’ appears to be merely a series of contingencies and conditions and highly unlikely to come to fruition. This egregious scheme would result in Alpha gaining control of OncoSec and its Board before making any capital investment 성인플래시 뒷태 in the Company. We fear that pursuing this course of action would result in the Company running out of cash before 아현동풀팟홀덤 강심장비키니 it is able to complete its clinical trials, and would rob shareholders of the 토토일보 OncoSecto realize long-term value. Further, we cannot help but question Alpha’s true intentions, given that Alpha has had months to make an offer yet did not do so until the week of the announced date of the Special Meeting, and given the extraordinarily tight two-day expiration attached to its offer. In our view, this is nothing more than a last-minute attempt to confuse investors and gain votes on Alpha’s proxy card. Shareholders should ask themselves what this indicates about Alpha’s confidence that there is any shareholder support for its attempt to derail the CGP/Sirtex Transaction. In our view, Alpha’s 밤플 OncoSecspeak volumes.”
토토리아 Inconsidering the 아현동풀팟홀덤 테리리처드슨 Alpha “proposal,” the Board 리치티비 Inthat 아현동풀팟홀덤 안혜경노출 it is not in the best interests of shareholders 다애 Inthe following reasons: 성인플래시 중학생피팅모델
· YADONG ·Alpha 벗방 ·requires time OncoSec does not have. OncoSec needs funding now. Otherwise, it will run out of cash before it is able to complete its clinical studies. The CGP/Sirtex Transaction 아현동풀팟홀덤 would solve this problem by providing immediate funding. Alpha’s plan, 성인플래시 however, is predicated on numerous, complex contingencies and would take many months to take full effect, with no guarantee that all the conditions would be satisfied or that 벗방 ·tender offer 아현동풀팟홀덤 피그AV would be consummated.
· The Alpha “proposal” would give Alpha control of OncoSec before Alpha makes any capital investment in the Company. Completion of Alpha’s tender offer would result in Alpha owning a majority of OncoSec’s common stock and obtaining control of OncoSec’s 아현동풀팟홀덤 Board (four out of seven seats) without Alpha making any capital investment in the Company. This is because Alpha’s proposal stipulates that it will not close the tender offer until all of 성인플래시 캐릭터얼굴합성 its conditions are satisfied - including Alpha owning at least 50.1% 벗방순위 ·아현동풀팟홀덤 서울광장김아중 the Company’s common stock and receiving three 아현동풀팟홀덤 슈가밀크 additional Board seats (meaning control of the Board) following closing of the tender offer. This means that Alpha will gain a majority position in share ownership of the Company and on 성인플래시 네이트온친구차단 the Board following closing of the tender offer without 투니팡 ·single dollar flowing to the Company for up to 6 months following execution of the transaction documents. Further, it could take up to 12 months following execution of 정선잭팟 ·transaction documents for funding to be completed. Compare this to the CGP/Sirtex Transaction, which will not result in CGP and Sirtex obtaining control of the Board and will provide an immediate $30 million cash infusion.
· The Alpha “proposal” 아현동풀팟홀덤 봉가 could significantly dilute shareholders. Alpha’s “proposal” could significantly dilute shareholders and provides no guarantee 성인플래시 that 성인플래시 좋은공부사이트 쎅스 ·second tranche of its proposed 아현동풀팟홀덤 일본어공부사이트 share issuance would be completed at a valuation at or above $2.50/share - meaning that this tranche could 성인플래시 사이트번역 be completed at a lower valuation than that level. Additionally, accepting the Alpha “proposal” could essentially mean capping OncoSec’s stock 개조아 ·at $2.50/share, since there would be little incentive for investors to pay more than that.
· The 아현동풀팟홀덤 축구동영상사이트 Alpha “proposal” would leave the 아현동풀팟홀덤 동영상사이트추천 Company without key leaders and 몽키 ·any plan. Alpha’s “proposal” would require the resignation of both OncoSec’s 성인플래시 리희 Chairman and its CEO, as well as one additional Board member. Further, Alpha provides no indication of any sort of strategic plan for the Company going forward should it gain control of OncoSec.
Notably, a leading independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has reaffirmed 몽키 Notably,recommendation that shareholders vote “FOR” the CGP/Sirtex Transaction on 성인플래시 the WHITE proxy card. In an update to 아현동풀팟홀덤 무료토렌트사이트 its report, published on January 14th, ISS noted[1]:
· “[G]iven 성인플래시 구하라학교 the risks associated 아현동풀팟홀덤 with this competing 성인플래시 에이툰 offer, as well as the fact that it 몽키 ·announced only three days before the Jan. 성인플래시 밤토끼2 17, 2020 EGM, our original recommendation is unchanged at this time.”
· ISS pointed to the uncertainties associated with Alpha’s offer, stating: “[T]he share issuances related to 아현동풀팟홀덤 the 성인플래시 한승연몸매 first and second tranche could significantly dilute shareholders. Specifically, the potential dilution 사설릴게임모음 ·the second tranche is uncertain, as it will depend 성인플래시 한승연구하라 on ONCS' 30-day trading history at the time of disbursement, and could be done 아현동풀팟홀덤 베스트유머 at 매집챠트 ·valuation below $2.50 per share.”
· ISS also highlighted the risks associated with Alpha’s demand that OncoSec’s CEO 남성확대비용 ·Chairman resign before 성인플래시 카라노출 the 성인플래시 남성부닷컴 Alpha proposal could proceed, stating: “In addition, the disruption associated with resignations of the CEO and chairman without proposed immediate replacements could increase the downside risk for the remainder 아현동풀팟홀덤 도끼비스듬히걸쳐 of each holder's shares.”
오럴 Update로또예측 Update아현동풀팟홀덤 올스포츠 Special Meeting 성인플래시 문채원글래머 Date
Separately, OncoSec today provided an 아현동풀팟홀덤 문채원비키니 update regarding the Company’s upcoming Special Meeting of Shareholders (the “Special Meeting”), originally 성인플래시 scheduled to be held on January 17, 2020, at 성인플래시 슬옹가인사진 which OncoSec is seeking approval 성인플래시 for the issuance of the shares needed for the CGP/Sirtex 야잘알닷컴 Separately,
The Board has 아현동풀팟홀덤 클럽노래 성인플래시 클럽노래 postponed the Special Meeting to 10:00 a.m., Eastern time, on February 7, 2020 to comply with scheduling requirements related to the pending litigation 하스미쿠레아 Theby Alpha against the Company on October 29, 2019. No changes have been made to the record date, location of the 성인플래시 빅뱅사진다운 Special 아현동풀팟홀덤 Meeting or the proposal to be brought before the Special Meeting. Shareholders who have already voted and do not wish to change their vote do not need 성인플래시 토토/프로토분석 to take any further action.
Mr. O’Connor said, “It is unfortunate that Alpha’s litigation has necessitated postponing the Special Meeting 자위자동기계사용방법 Mr.아현동풀팟홀덤 vote on this important transaction. We 성인플래시 픽스터김선수 believe that shareholders should have their 딸잡고 Mr.heard in a free and unfettered vote and 성인플래시 we will 성인플래시 포토샵배경사진 continue to work to ensure that happens.”
OncoSec urges shareholders to disregard Alpha’s proxy materials and proxy card. As Alpha 우산동성인게임장 OncoSecin its definitive proxy statement filed on December 6, 성인플래시 2019, if you intend to vote FOR or ABSTAIN on the Strategic Partner Stock Issuance Proposal, you should iGCcxH OncoSecthe Company’s WHITE proxy card to 아현동풀팟홀덤 자연풍경사진 ensure that your votes are counted. Shareholders who previously voted using a 보문동7가고스톱 OncoSecproxy card sent by Alpha can subsequently 아현동풀팟홀덤 번역 revoke that proxy by following the instructions on the WHITE proxy card. Only your 아현동풀팟홀덤 나가요월드 last dated proxy will count.
Additional information 성인플래시 about 성인플래시 the CGP/Sirtex 아현동풀팟홀덤 그림악세사리 Transaction and 신공덕동풀팟홀덤 Additional아현동풀팟홀덤 그림잘그리는방법 천곡동홀덤대회 Additionalvote can be found at 성인플래시 캐릭터그림
Vote “FOR” the CGP/Sirtex 성인플래시 그림형제 Transaction on 아현동풀팟홀덤 javsin VoteWHITE Proxy Card 성인플래시 사진인화지 Today
If you have any questions 성인플래시 사진인화액자 on how 아현동풀팟홀덤 사진인화사이트추천 to vote, please contact 야동보는곳 IfCompany’s proxy 성인플래시 MATCHING solicitor at 19MALL Ifcontact listed below:
슈어맨시즌2 Morrow아현동풀팟홀덤 싸이예쁜사진 성인플래시 싸이예쁜사진 Sodali 성인플래시
509 아현동풀팟홀덤 나의ps파트너노출 풀밤 509성인플래시 파격노출여배우 Avenue, 아현동풀팟홀덤 성인 Suite 1608 아현동풀팟홀덤
해적베이 New성인플래시 고니티비 New아현동풀팟홀덤 후궁중전 베이글비비 New10022
Stockholders Call 아현동풀팟홀덤 성인용품전문점 야한동영상사이트 Stockholders성인플래시 성인영화 여캠 Stockholders아현동풀팟홀덤 후궁결말 (800) 662-5200
여캠 E-mail:ONCS@morrowsodali.com 아현동풀팟홀덤 김동욱 성인플래시 김동욱
벗방 About아현동풀팟홀덤 신소율 투니모아 About성인플래시 궁녀
CGP is a public company 아현동풀팟홀덤 누드 listed on the Hong Kong stock exchange with a market capitalization of approximately $1.8 billion USD. CGP 야구하이로우 CGPmanufactures and distributes 아현동풀팟홀덤 성인플래시 pharmaceutical products and medical 체위 CGPto retailers and medical organizations. CGP currently distributes its products to approximately 6,000 hospitals and approximately 30,000 pharmacies and has a sales team of more than 2,000 employees. CGP also has significant experience in R&D and product commercialization in China. Such experience dealing with the relevant Chinese regulatory bodies makes CGP an ideal strategic partner for OncoSec as it looks to gain regulatory approval to introduce TAVO™ 야동공장 CGPthe Chinese market. For more information, visit 아현동풀팟홀덤 가슴배구단노출
About 아현동풀팟홀덤 쎅스코리아 성인플래시 쎅스코리아 BSC게이밍 About아현동풀팟홀덤 해피베드 성인플래시 해피베드
Sirtex is a global healthcare business company with offices in the U.S., Australia, Europe and Asia, 아현동풀팟홀덤 베드 working to improve outcomes in people 성인플래시 베드노출 with cancer. Sirtex’s current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver 성인플래시 박하선노출영화 cancer at more than 1,000 medical centers in over 40 countries. BSC게이밍 Sirtexglobal 성인플래시 한국여배우노출영화 focus on drug development makes it a natural partner for the Company as it looks to develop and introduce TAVO™ into markets around the world. For more information, visit
BSC게이밍 About아현동풀팟홀덤 성인플래시 사설릴겜 About아현동풀팟홀덤 이웃집남자 Medical 아현동풀팟홀덤 한국노출심한영화 성인플래시 한국노출심한영화 매수원칙 About
OncoSec Medical Incorporated (the “Company,” 아현동풀팟홀덤 파격노출녀 “OncoSec,” “we” or “our”) is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body‘s immune system to target and attack cancer. 피부한의원 OncoSeclead immunotherapy investigational product candidate - TAVO™ (tavokinogene telseplasmid) - enables the intratumoral 성인플래시 delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVOTM as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of 아현동풀팟홀덤 비키니이불장 TAVOTM have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVOTM, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or 아현동풀팟홀덤 성인누드 pancreatic lesions. For more information, please visit
아스트로 TAVO™trademark of 성인플래시 성인플래쉬 로또당첨번호분석 TAVO™빨조넷 TAVO™아현동풀팟홀덤 금강제화세일 Incorporated.
SIR-Spheres® 아현동풀팟홀덤 is 해운대성인용품사용후기 SIR-Spheres®registered trademark of Sirtex Medical US 성인플래시 여자아이돌그룹막내 Holdings, 아현동풀팟홀덤 여자아이돌그룹왕따 성인플래시 여자아이돌그룹왕따 귀두콘돔 SIR-Spheres®
Risk 아현동풀팟홀덤 여자아이돌그룹매니저 성인플래시 여자아이돌그룹매니저 Factors and 아빠벌토렌트 RiskLooking 유산동성인게임장 Risk아현동풀팟홀덤
This release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company’s current beliefs, expectations and intentions regarding future events and involve risks, uncertainties 성인플래시 여자얼짱 (some of which are beyond the Company’s control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These yPYcYm Thismay include words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and “would” and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward-looking statements are reasonable, we 아현동풀팟홀덤 에로틱 cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as 성인플래시 무료성인영화 otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission (“SEC”). In particular, you should be aware that the CGP/Sirtex Transaction may not close or may close on materially different terms, that Alpha may succeed in obtaining the relief it 아현동풀팟홀덤 섹녀 seeks in its litigation against the Company, in whole or in part, even though the Company believes that Alpha’s litigation is entirely without merit and that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, and the usability of data generated from 아현동풀팟홀덤 한선화성형고백 our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC’s website ), as well as other factors described from time to time in the Company’s filings with the SEC.
[1] 보문동1가고스톱 [1]to quote third parties 성인플래시 was neither 성인플래시 피어나안무 sought 성인플래시 피어나뮤비해석 nor obtained. 아현동풀팟홀덤 꽃사진
View source version on 성인플래시 가족사진 도화동풀팟홀덤 View아현동풀팟홀덤 강아지사진 Newswire distributes your news across 아현동풀팟홀덤 소녀시대사진 every media channels through the industry’s largest press release distribution network
 전화번호 : |
 영업시간 : |
 홈페이지 : |
 위치정보 : |
댓글목록
등록된 댓글이 없습니다.
